Chaib, Selim https://orcid.org/0000-0003-0497-2002
López-Domínguez, José Alberto https://orcid.org/0000-0001-8733-3294
Lalinde-Gutiérrez, Marta https://orcid.org/0000-0002-9858-8775
Prats, Neus
Marin, Ines
Boix, Olga
García-Garijo, Andrea https://orcid.org/0000-0002-7775-0737
Meyer, Kathleen
Muñoz, María Isabel
Aguilera, Mònica https://orcid.org/0000-0003-0763-7947
Mateo, Lidia https://orcid.org/0000-0002-9076-4025
Stephan-Otto Attolini, Camille https://orcid.org/0000-0001-8045-320X
Llanos, Susana https://orcid.org/0000-0002-8555-9326
Pérez-Ramos, Sandra https://orcid.org/0000-0002-3612-4027
Escorihuela, Marta
Al-Shahrour, Fatima https://orcid.org/0000-0003-2373-769X
Cash, Timothy P.
Tchkonia, Tamara https://orcid.org/0000-0003-4623-7145
Kirkland, James L. https://orcid.org/0000-0003-1676-4905
Abad, María https://orcid.org/0000-0002-1462-2498
Gros, Alena https://orcid.org/0000-0002-1207-1880
Arribas, Joaquín https://orcid.org/0000-0002-0504-0664
Serrano, Manuel https://orcid.org/0000-0001-7177-9312
Article History
Received: 14 July 2022
Accepted: 14 December 2023
First Online: 24 January 2024
Competing interests
: M.S. is a shareholder of Senolytic Therapeutics, Life Biosciences, Rejuveron Senescence Therapeutics and Altos Labs. S.C. has received royalties from Rejuveron Senescence Therapeutics. T.P.C. is a shareholder of Rejuveron Senescence Therapeutics. A.G. performs consulting work for Rejuveron Senescence Therapeutics. T.T. and J.L.K. have a financial interest related to this research including patents and pending patents covering senolytic drugs and their uses, which are held by the Mayo Clinic. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with the Mayo Clinic conflict of interest policies. The other authors declare no competing interests. The funders had no role in study design, data collection and analysis, decision to publish or paper preparation.